Northwestern Mutual Wealth Management Co. Acquires Shares of 356,505 IQVIA Holdings Inc. $IQV

Key Points

• Northwestern Mutual Wealth Management acquired 356,505 IQVIA shares worth approximately $68.9 million, representing about 0.22% of the company. Institutional investors collectively own 89.62% of IQVIA.
• IQVIA exceeded quarterly expectations, reporting $3.15 earnings per share versus the $3.03 consensus and $4.37 billion in revenue, up 8.7% year over year. The company also authorized a $2 billion share-repurchase program.
• IQVIA shares opened at $260.17 near their 12-month high, while analysts maintained an overall “Moderate Buy” rating with a consensus price target of $241.88; insiders have sold roughly $3.1 million of stock over the past 90 days.

Northwestern Mutual Wealth Management Co. bought a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 356,505 shares of the medical research company's stock, valued at approximately $68,884,000. Northwestern Mutual Wealth Management Co. owned approximately 0.22% of IQVIA as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of IQV. International Assets Investment Management LLC purchased a new position in IQVIA in the 4th quarter valued at approximately $27,000. Gilpin Wealth Management LLC purchased a new stake in shares of IQVIA during the fourth quarter worth $27,000. CrossGen Wealth LLC bought a new position in shares of IQVIA in the fourth quarter worth $28,000. Activest Wealth Management grew its position in shares of IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company's stock valued at $31,000 after purchasing an additional 118 shares in the last quarter. Finally, Financial Freedom LLC bought a new stake in shares of IQVIA during the 1st quarter valued at $25,000. 89.62% of the stock is owned by institutional investors.

Insider Activity at IQVIA

In related news, insider Keriann Cherofsky sold 558 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company's stock, valued at $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider W Richard Staub sold 5,500 shares of the firm's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider owned 13,312 shares in the company, valued at $3,097,436.16. The trade was a 29.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 12,913 shares of company stock valued at $3,098,793 over the last ninety days. 1.70% of the stock is currently owned by insiders.

IQVIA Stock Up 1.6%

Shares of NYSE IQV opened at $260.17 on Friday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The business has a 50-day moving average of $213.32 and a 200-day moving average of $187.52. The firm has a market capitalization of $42.82 billion, a price-to-earnings ratio of 32.28, a PEG ratio of 2.21 and a beta of 1.18. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $260.40.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. IQVIA's quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the firm posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a stock buyback program on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

IQV has been the subject of several analyst reports. JPMorgan Chase & Co. raised their target price on IQVIA from $225.00 to $285.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Morgan Stanley reissued an "equal weight" rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. BMO Capital Markets boosted their price objective on shares of IQVIA from $210.00 to $270.00 and gave the company an "outperform" rating in a research note on Wednesday, July 29th. Barclays reiterated an "overweight" rating on shares of IQVIA in a research note on Tuesday, July 28th. Finally, Royal Bank Of Canada raised their price target on shares of IQVIA from $221.00 to $247.00 and gave the company an "outperform" rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, IQVIA currently has an average rating of "Moderate Buy" and a consensus price target of $241.88.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source